Adalvo is on track to complete the global dossier for Ceftazidime + Avibactam by year-end.
Developing this complex antibiotic combination required overcoming significant challenges, including securing limited API sources and ensuring that the active pharmaceutical ingredients meet target characteristics through a well-established aseptic manufacturing process.
With a well-defined IP strategy, Adalvo has secured a clear pathway for a Day-1 launch in key markets. This unique development targets global markets, including the US, Europe, and other Rest of the World geographies.
Based on Zavicefta (EU) and Avycaz (US), Ceftazidime + Avibactam is a critical treatment for serious bacterial infections, including complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI) – including pyelonephritis – and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).
With $659 million in total IQVIA MAT sales in 2024 and a 3-year CAGR of 23%, Ceftazidime + Avibactam shows strong market potential.
Adalvo’s strategic approach ensures that patients and partners alike benefit from a high-quality, affordable solution to combat these life-threatening infections.
Click Here To View Adalvo's Anti-Infectives Portfolio
Partner with Adalvo to drive the future of infectious disease treatment.
Contact our team to explore commercial opportunities.